X

Drug Profile

Research programme: cancer therapeutics - Bristol-Myers Squibb/Exelixis

Latest Information Update: 04 Nov 2017

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb; Exelixis
Class Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Cancer

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
22 Feb 2011 Collaboration is ongoing in the US
22 Jan 2008 Bristol-Myers Squibb exercises its option to develop and commercialise XL 139 under the terms of this collaboration

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com